Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Avigad

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
European Journal of Human Genetics : EJHG|January 1, 1994
Origins of hyperphenylalaninemia in IsraelS Kleiman, S Avigad, L Vanagaite, et al.
Bone Marrow Transplantation|March 21, 2007
Ewing Sarcoma tumor cells express CD34: implications for autologous stem cell transplantationI Yaniv, J Stein, D Luria, et al.
Leukemia|March 23, 1999
TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemiaS Avigad, G Kuperstein, J Zilberstein, et al.
Leukemia|February 29, 2008
Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?E Fronkova, E Mejstrikova, S Avigad, et al.
Clinical Genetics|November 4, 2016
Homozygous deletion of RAG1, RAG2 and 5' region TRAF6 causes severe immune suppression and atypical osteopetrosisM Weisz Hubshman, L Basel-Vanagaite, A Krauss, et al.
Leukemia|March 13, 2019
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Leukemia|January 16, 2020
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
European Journal of Human Genetics : EJHG|January 1, 1994
Origins of hyperphenylalaninemia in IsraelS Kleiman, S Avigad, L Vanagaite, et al.
Bone Marrow Transplantation|March 21, 2007
Ewing Sarcoma tumor cells express CD34: implications for autologous stem cell transplantationI Yaniv, J Stein, D Luria, et al.
Leukemia|March 23, 1999
TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemiaS Avigad, G Kuperstein, J Zilberstein, et al.
Leukemia|February 29, 2008
Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?E Fronkova, E Mejstrikova, S Avigad, et al.
Clinical Genetics|November 4, 2016
Homozygous deletion of RAG1, RAG2 and 5' region TRAF6 causes severe immune suppression and atypical osteopetrosisM Weisz Hubshman, L Basel-Vanagaite, A Krauss, et al.
Leukemia|March 13, 2019
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Leukemia|January 16, 2020
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Pageof 7